Advanced Imaging and AI in Drug Development: Autoimmunity
Join Dr. Olga Kubassova’s live webinar “Advanced Imaging and AI for Clinical Drug Development: Autoimmunity” to discuss the role of medical imaging markers and AI in drug development for auto-immune diseases. The session will begin with Dr. Kubassova’s talk followed by the live Q&A with the audience.
Key Discussion Points:
- The connection between the development of novel therapeutics and data sciences.
- The practical use of imaging in clinical trials: patient stratification and drug efficacy.
- Modern trial infrastructure to enable global reach and use of AI.
Date and Time:
Tuesday 7th April 2020, 11:00-12:00 am ET (16:00-17:00 GMT)
About the Webinar:
This webinar is jointly organized by IAG, Image Analysis Group, World Molecular Imaging Society (WMIS) and Harvard Medical School.
To succed in drug development, we need clear understanding of the disease biology and objective efficacy assessment for a novel treatment.
Imaging based endpoints support our understanding of the early treatment response and can predict trial outcomes. Optimal use of medical imaging has become critical to the modern trial designs and plays an essential role in de-risking R&D process and biotech investment.
AI-enabled methods for patient stratification and drug efficacy assessment can focus budgets and resources.
Advanced imaging, AI and global set-up of a trial demand modern infrastructure that is compliant with regulatory requirements but agile and fit for purpose of the trial. In the webinar, we will discuss the use of a cloud platform in trial settings.
With Covid-19 impact, we should prepare making treatment efficacy decisions with much smaller number of patients. Thus, better infrastructure and richer data will become the key drivers of successful trial outcome.
Join the webinar and live Q&A!
About Dr. Olga Kubassova:
Dr. Olga Kubassova, CEO of IAG, Image Analysis Group. She is a mathematician, computer scientist and entrepreneur, playing a significant role in the development and use of medical imaging in clinical research and diagnosis. She is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative. She is an editor and reviewer of several scientific journals. She is also a founding member of “The 2% Club” to support women in leadership positions, a fellow of the Royal Society of Medicine, Royal Society of Engineering, 4-time winner of the national and international “Entrepreneur of the Year” award.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin
Join us at BIO International Convention in Boston 5th-8th June 2023
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.